Molecular lesions of genes encoding for transcriptional regulatory proteins are common oncogenic events in hematologic malignancies. Transcriptional activation and repression both occur by virtue of the choreographed recruitment of multisubunit cofactor complexes to target gene loci. As a consequence, the three-dimensional structure of the target gene is altered and its potential to support transcription is increased or decreased. The complexity of the transcriptional process offers a rich substrate for designing therapeutic agents. The objective of such 'transcription therapy' is to regain control over cohorts of target genes and restore the normal genetic and epigenetic programming of the cancer cell. The success of all-trans retinoic acid in the treatment of acute promyelocytic leukemia indicates that transcription therapy can be highly effective and safe. A classification scheme of these therapeutic strategies is proposed herein, which allows predictions to be made regarding specificity, efficacy, disease spectrum and side effects. This framework could help facilitate discussion of the mechanisms of action of transcription therapy drugs as well as the design of preclinical and clinical trials in the future.
Transcriptional regulators are mutated in hematologic malignancies
Leukemias and lymphomas often misexpress or harbor mutations of transcriptional regulatory proteins. [1] [2] [3] Many of these are proto-oncogenes that play crucial roles in hematopoiesis, and confer aberrant differentiation, survival and growth characteristics when deregulated. For example, the BCL6 (B-cell lymphoma -6) protein is normally required for germinal center formation by B cells, but mediates lymphomagenesis when constitutively expressed 4, 5 (Cattoretti et al. Blood 2003; 102: 136a). The AML-1 (acute myeloid leukemia-1) transcription factor is required for normal hematopoiesis, but becomes leukemogenic when fused to the ETO (eight twenty one) corepressor in t(8;21) AML. 6 It is not surprising that aberrant transcriptional control is a frequent occurrence in hematologic malignancies, since proteins that behave as master regulators of gene expression could seriously perturb cellular homeostasis in the carefully regulated progression of hematopoiesis. Indeed, hematopoietic compartments would seem to be fertile terrain for malignant transformation. For example, the constant recruitment of stem cells into the rapidly proliferating progenitor compartment requires coordinated actions of proto-oncogenes and differentiation regulators. 7, 8 Similarly, in germinal center reactions, B cells proliferate rapidly while simultaneously undergoing DNA damage as a byproduct of class switch recombination and somatic hypermutation. 9 This physiological state of genomic instability provides a fertile ground for genetic events that could lead to lymphomagenesis. 10 In either case, aberrant transcriptional control provides a growth and survival advantage for the involved cells.
The concept of transcription therapy evolved from the realization that transcription factors play critical roles in molecular pathogenesis, and that specific targeting of these proteins could restore cells to their physiological programming. The aim of transcription therapy is to regain control of gene pathways deregulated by aberrant transcription factors, with the expectation that reprogrammed cells would resume their normal function, become dormant or undergo cell death. Well-designed transcriptional therapeutic strategies would target tumor cells without significantly affecting other cellular processes. That such an approach is feasible and effective is demonstrated by the success of the first bona fide transcription therapy agent, alltrans retinoic acid (ATRA), in the treatment of acute promyelocytic leukemia (APL). 11 Progress in understanding the basis of eukaryotic transcription is accelerating. Accordingly, the experimental therapeutics field is at the threshold of designing and testing a number of novel transcription therapy agents.
The substrate for transcription
The substrate for transcriptional repression and activation are the individual gene loci, which consist of the mixture of DNA and proteins known as chromatin. 12 Chromatin is physically modified by transcriptional complexes in such a way as to change the rate of expression of their encoded gene products. Genetic loci can also be viewed as information-rich environments, composed of two compartments that direct the functionality of the gene. These are: (i) the genetic compartment, comprised of the information contained in the base-pair sequence of DNA, and (ii) the epigenetic compartment, comprised of all of the information not contained in the basepair sequence of DNA. Epigenetic information includes DNA CpG methylation status, the location and histone isomer composition of nucleosomes, post-translational modifications of histone tails (ie the 'histone code') and other chromatinassociated proteins such as histone 1, sirtuins and HP1 (heterochromatin protein-1) [13] [14] [15] ( Figure 1 ). These information sets are integrated and modified by the collective actions of transcription factors and transcription cofactors.
From the epigenetic standpoint, CpG methylation silences genes, by either impeding binding of transcription factors that recognize CG containing sequences or by recruiting repressor proteins that bind specifically to methyl-CpGs. 16 The covalent modification of specific histone residues by acetylation, methylation, phosphorylation, ubiquitylation and others are a central component of epigenetic information. The mixture of histone modifications contained within each nucleosome provides binding surfaces for protein complexes that recognize specific configurations of these marks. 17 This combinatorial 'histone code' transmits epigenetic information to the transcriptional machinery as well as protein complexes involved in other processes such as DNA repair, mitosis and replication. 17 In turn, transcriptional cofactors alter the histone code through enzymatic activities that covalently modify histone tails.
Transcription factor binding requires the presence of respective consensus DNA-binding site in the target gene promoter or enhancer, and may be dependent on whether the DNA is methylated, or whether nucleosomes or other chromatinassociated proteins allow access to the binding sites. 18, 19 Transcriptional cofactors (ie coactivators and corepressors) can be recruited by transcription factors, or by directly binding to histones with specific post-translational modifications. 20, 21 Examples of the latter include the direct binding of the PCAF coactivator protein to acetylated lysine contained in histone tails 22 and binding of the HP1a chromatin silencing protein to methylated histone 3 lysine 9. 23 Histone code settings may also repel proteins, so that the NuRD corepressor complex is unable to bind histone 3 when methylated on lysine 4, which is a mark associated with transcriptionally active genes. 24 Recruitment of transcriptional complexes is thus dependent on the genetic and epigenetic configuration of each gene locus.
Controlling the activity of the entire cohort of genomic loci in response to the minute-to-minute needs of each cell of the organism requires an extensive network of transcription factors and cofactors that are exquisitely regulated through complex feedback mechanisms and epigenetic cues. Taken together, transcription factors can be defined as devices that integrate these signals by binding to specific gene loci and recruiting protein complexes that alter their chromatin structure. Thus, agents that target transcription complexes will result in epigenetic remodeling of gene loci. We propose here a simple model that allows predictions to be made regarding the impact of such agents on transcriptional and biological features of target cells.
A model for predicting the effects of transcription therapy drugs
In this scheme, transcriptional regulatory complexes are visualized as a three-tiered system (Figure 2a ).
Level one
The first level corresponds to transcription factors, defined as proteins that bind to a consensus DNA sequence in the promoters and enhancers of their respective direct target genes. Transcription factors themselves do not directly activate or repress expression of target genes. Rather, these proteins serve as recruiting mechanisms for specific combinations of cofactors that alter gene structure and expression rate. Transcription factors contain DNA-binding modules such as zinc-fingers or bHLH (basic helix-loop-helix) domains, and protein interaction domains such as BTB (bric á brac, tramtrack, broad complex) domains or KRAB (Krü ppel-associated box domains). 25 Thus, the main function of transcription factors is to provide specificity to transcriptional complexes by choosing which genes or regions of the genome will be epigenetically modified.
Level two
The second level in the transcriptional complex corresponds to scaffold-like proteins containing multiple protein-protein interaction motifs. Level-two proteins are recruited by transcription Figure 1 Chromatin configuration of gene loci determine their transcriptional output. The ability of a gene to be transcribed is a continuum dependent on interactions between the genetic and epigenetic components of the gene locus. Genes become progressively silenced as they acquire transcriptional repressors and corepressors, repressive histone modifications, heterochromatin proteins, linker histone 1 and dense packing of nucleosomes. Genes become more active as they acquire transcriptional activators, activating histone modifications, loose packing of nucleosomes and assemble the general transcriptional machinery; 10 nm ¼ the 10-nmwide chromatin fiber (string of beads), 30 nm ¼ the 30-nm-compacted chromatin fiber.
Figure 2
A model that predicts the effects of transcription therapy. Panel a: A transcriptional complex, which is composed of a level-one protein (ie a DNA-binding transcription factor) that contains protein interaction motifs to recruit level-two scaffold-like cofactor proteins. These contain multiple protein interaction surfaces to recruit levelthree proteins, which possess enzymatic activity and can covalently alter the structure of the target gene. Panel b: A dartboard graph where the center corresponds to level-one proteins and the periphery to levelthree proteins. The more proximal to level one, the more specific the therapy, while the more distal to level one, the broader the spectrum of susceptible tumors to a potential transcription therapy agent. Proximal targeting may also be more effective as it is likely to result in complete loss of function of transcriptional complex vs distal targeting, which only blocks part of the transcriptional complex.
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A Melnick factors and provide the skeleton or framework for establishment of a large transcriptionally active complex, but generally do not contain enzymatic activities. Some of these cofactors are mutated in hematologic malignancies, such as the ETO protein in t(8;21) AML. 26 Others such as the SMRT (silencing mediator of retinoid and thyroid receptor) and N-CoR (nuclear receptor corepressor) corepressor proteins are not mutated, but are implicated as cofactors for oncogenic transcription factors such as PML/RARa (promyelocytic leukemia protein/retinoic acid receptor alpha), AML-1/ETO and BCL-6.
27-29 Level-two proteins regulate a greater cohort of genes than level-one proteins, as they interact with a number of transcription factors.
Level three
Level-three proteins are enzymes, such as histone deacetylases (HDACs) and acetyl transferases (HATs), that covalently modify histones and other components of transcriptional complexes. These enzymes are recruited by level-two and level-one proteins. Level-three proteins are nonspecific in that they are involved in transcriptional regulation of many genes, and may have other functions unrelated to transcriptional control. Accordingly, HDACs are a common mechanism in mediating repression by oncogenic transcription factors involved in hematologic malignancies (such as the APL RARa fusions, AML-1/ETO, CBFb/MYH11, TEL/AML-1, BCL6). 30 Many transcriptional/epigenetic regulatory complexes have been biochemically purified and are composed of level-two and level-three proteins. Examples include the Sin3a, NuRD and N-CoR complexes. [31] [32] [33] A partial list of level-one, level-two and levelthree proteins involved in or potentially relevant for hematologic malignancies is listed in Table 1 .
Caveats to this model include the facts that: (i) some proteins may have properties of more than one level. For example, the very large MLL protein, frequently translocated in acute leukemias, can bind to AT-rich DNA sequences, may act as a large scaffold, and also has histone methyltransferase activity. 34 MLL thus has properties consistent with all three levels. However, MLL was recently shown to cleave into two subunits that can then bind together, but in which the DNA-binding domain and enzymatic histone methyltransferase activities are on different portions. 35 Thus, the MLL protein divides into subunits with either level 1/2 or level 2/3 activity, respectively.
(ii) A number of level-one transcription factors also function as level-two cofactor proteins. For example, the PLZF transcriptional repressor can act as a corepressor for the vitamin D receptor, 36 while BCL6 can act as a corepressor for AP-1. 37 Finally, each transcription factor may form slightly different complexes at respective target promoters. Accordingly, recent data suggest that BCL6 represses survival-related genes through the SMRT corepressor complex, and differentiation related genes through the NuRD corepressor complex. [38] [39] [40] Therefore, corepressor complexes may somehow provide gene specificity to transcription, and it is not appropriate to assume that all target genes of a given level-one protein will be affected in the same way by blocking its interaction with a specific cofactor. The predictions of our three-level model may still apply to such proteins so long as one keeps in mind these nuances.
Classification of transcription therapy
The three-tiered model allows predictions to be made regarding the biological and therapeutic effects of transcription therapy agents. If one views the three levels as a dartboard graph as shown in Figure 2b , the major prediction is that the closer the target is to the center (level one), the more effective and more disease specific the therapy will be. While the further to the periphery you go (ie towards level 3), a greater disease spectrum can be treated, but likely with less efficacy. According to the proximity of their target to specific DNA-binding sites, agents that target level-one proteins would be considered 'proximal' agents (narrow spectrum), and those that target levels two and three -'distal' agents (broad spectrum) ( Table 2) .
The rational for these statements stems from the fact that transcription factors (ie level-one proteins) are frequently mutated in hematologic malignancies and play fundamental roles in molecular pathogenesis. Therefore, our model predicts that targeting oncogenic level-one proteins will have a potent biological and therapeutic impact, but will be limited to a specific molecular subtype of disease. For example, in APL, the aberrant transcription factor PML/RARa plays a critical role in determining disease biology and phenotype. 41 Targeting PML/ RARa with its specific ligand ATRA is a form of proximal (levelone-targeted) transcription therapy. ATRA fulfills the predictions of our model in that it induces complete remission in 90% of patients with APL, but is not effective in other leukemias.
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Targeting a level-one protein should re-establish normal expression of its direct target genes and should specifically reprogram the cancer cell back to a more physiological state (such as the myeloid differentiation observed in APL patients treated with ATRA). Since cancer is a multihit disease, such specific targeting is unlikely to be curative as a single agent, but would significantly improve therapeutic efficacy of additional agents and would likely have a favorable toxicity profile compared to nonspecific drugs. Accordingly, in APL, ATRA therapy alone does not cure the disease, but provides improved event-free and overall survival in combination with other agents, and has a favorable side effect profile so long as the leukemia differentiation syndrome is recognized early.
11,42
Level-three proteins interact with transcription factors involved in different molecular subtypes of leukemias and lymphomas. The example of HDACs as a common mechanism of aberrant transcriptional repression in leukemia and lymphoma was already mentioned above. Targeting level-three proteins would therefore be expected to have an impact in many different diseases. On the other hand, transcription factors function through more than just one level-three mechanism, so that their effects would be only partially compensated by a distally targeted drug. Level-three proteins may also be involved in processes other than transcriptional control. HDACs deacetylate microtubules, heat-shock proteins and are involved in angiogenesis. 43 Taken together, level-three targeting should be applicable to broad spectrum of diseases, but will be less effective and specific than proximal targeting. Moreover, the fact that other cellular processes can be affected suggests that even in cases where level-three agents are most effective, the transcriptional effects may not be the most significant biological effect. An additional consequence of lack of transcriptional specificity could be unexpected side effects such as the fatigue and cardiotoxicity observed with the HDAC inhibitor (HDI) depsipeptide. 44 In between these two extremes are the level-two proteins. Some are involved in hematologic diseases by translocations or amplification such as ETO and Bmi1 (a Polycomb protein), respectively. 6, 45 Although less is known about these proteins, our model predicts they would have intermediate effects as targets. They are probably somewhat more specific than level three since they interact with a smaller subset of transcription Transcription therapy A Melnick factors and few are known to be involved in other processes than transcription.
Hitting the dartboard with transcription therapy drugs
A final utility of the three-level model is that it highlights and contrasts different ways in which transcription can be targeted according to the nature of the target protein (Figure 3) . From proximal to distal, target genes of level-one proteins can be targeted by artificial transcription factors, while protein-protein interactions between the components of the different levels can be disrupted by peptides or small molecules, and the enzymatic activities of level-three proteins can be targeted by small molecule inhibitors. An alternative approach to targeting any of these proteins is using antisense strategies such as been reported for the myb transcription factor (level one) 46 and for specific DNA methyltransferases (level three). 47 Regardless of A partial list of transcription factors and cofactors involved directly or indirectly in oncogenic gene regulation. The name, level, function, disease association and examples of published inhibitors are shown. A selection of reviews and primary data concerning these proteins is included (many other seminal papers on these topics are available, but are not included due to space concerns). A comparison of the predicted specificity for a given cohort of target genes, efficacy in reversing the primary oncogenic transcriptional mechanism, the spectrum of diseases likely to respond to the therapeutic agent, likelihood of nontranscriptional effects due to the involvement of the target in other biological processes and some of the mechanisms for therapeutic targeting of the respective proteins.
Transcription therapy A Melnick the targeting method, disease and transcriptional specificity is likely to be greater the more proximal the therapeutic agent is to the DNA-binding site of the entire transcriptional complex. Artificial DNA-binding motifs such as zinc-fingers can be designed to bind to a specific DNA sequence. 48 Libraries of zinc-fingers exist that can be selected to bind to a sequence of choice and fused to an activation or repression domain to turn on or off the desired target genes. Zinc-finger constructs can thus compete for access of an oncogenic transcription factor to its target genes, 49 or can modulate expression of specific genes. 50 The latter approach has been used experimentally, for example, to repress expression of VEGFA (vascular endothelial growth factor A) in glioblastomas. 51 Delivery of such therapeutic transcription factors requires a gene therapy approach with vector-dependent expression in target cells. 48 The targeting of protein-protein interactions can be achieved by directly blocking protein-protein interface with peptides or small molecules. It is important, however, to keep in mind that protein interaction domains may be conserved within families of transcription factors, and care must be taken to design peptide or small molecule drugs to be as specific as possible for the intended target. Peptides that disrupt known protein interaction interfaces can be isolated by phage display 52 or by screening peptide aptamers. 53 A recent report identified peptide aptamers that bind the STAT3 dimerization domain, block its transcriptional activity and caused apoptosis when transduced into myeloma cells. 54 Determination of the structure of the interface between proteins allows researchers to design specific and potent peptide inhibitors. Together with our collaborators, we recently characterized, by X-ray crystallography and functional assays, the interface through which the BCL6 oncogenic transcriptional repressor recruits the level-two scaffold-like corepressor protein SMRT. 55 Based on these data, we designed a peptide inhibitor that blocks the interaction of these two proteins. This BCL6 peptide inhibitor (BPI) reactivated BCL6 target genes, and caused apoptosis and growth suppression of DLBCL cells. 39 Consistent with our predictions for proximal transcription therapy, BPI was nontoxic to animals and potently and specifically blocked the activity of BCL6 in vivo. 39 In another study, larger fragments of the N-CoR corepressor was used to compete endogenous corepressors away from the leukemia fusion proteins PML/RARa ad AML1/ETO. 56 Delivery of peptide therapeutic agents as described in these examples is greatly facilitated by fusing them with protein transduction domains (PTDs), which mediate highly efficient penetration into cells both in vitro and in vivo. 57 PTDs mediate receptor-independent cell penetration by binding to lipid rafts and triggering macropynocitosis. 58 The PTD-fusion peptides are captured within endosomes, and then leak out into the cytoplasm. 58 PTDs such as the pTAT domain act also as nuclear localization signals, which is ideal for transcription therapy drugs. 39, 58, 59 Since all cells perform macropynocitosis, all cells are amenable to PTD-mediated peptide therapy. 58 Already, phase I/II clinical trials of PTD-delivered peptides are underway for several diseases.
Our model predicts that targeting DNA-binding domains would provide a more complete transcriptional blockade than targeting recruitment of level-two proteins. This is because transcription factors typically interact with many level-two proteins, each of which might preferentially regulate different subsets of target genes or which might need to cooperate to fully repress a common set of genes. If this were true, only a subset of target genes would be released by this more distal approach, or only partial transcriptional rescue would be achieved. For example, in the case of BCL6, a zinc-finger competitor protein blocked all the biological functions of BCL6, resulting in growth arrest, apoptosis and differentiation of lymphoma cells. 49 In contrast, blockade of SMRT recruitment to the BTB domain by BPI induced growth arrest and apoptosis but not differentiation. 39 Interestingly, B-cell differentiation but not apoptosis was induced by RNAi knockdown of a different level-two protein, MTA3, which recruits the NuRD repression complex to the middle region of BCL6. 38 Thus, proximal targeting by the zincfingers could presumably reactivate all BCL6 target genes and thus rescue all of its effects, while targeting of level-two recruitment could only reactivate specific subsets of BCL6 target genes dependent on either the MTA3 or SMRT corepressor proteins. [38] [39] [40] Small molecules are also suited for disrupting transcription complex protein-protein interactions and can similarly be identified through screening or structure-based design. Small molecules were recently isolated that block interaction of the TCF4 transcription factor with b-catenin, which acts as a leveltwo protein in transcription. 60 Another recent screen yielded small molecules that block the interaction of the CREB transcription factor with the CBP histone acetyltransferase coactivator (a level-three protein). 61 CREB is frequently highly expressed in AML and appears to play an important role in leukemia cell proliferation downstream of GM-CSF and IL-3 signaling. 62, 63 Several master regulatory transcription factors of hematopoiesis such as GATA-1, PU.1, AML-1 and CEBPa interact with each other in the context of their respective target genes, resulting in either synergy, such as between AML-1 with CEBPa 64 and AML-1 with MEF, 65 or antagonism, such as in the case of GATA-1 and PU.1. [66] [67] [68] These combinatorial switches determine lineage commitment and proliferative capacity of hematopoietic progenitor cells. Not surprisingly, dominant-negative or gain-of-function mutations in these factors have been identified in AMLs and could play an important role Targets for development of transcription therapy drugs. From proximal to distal, some of the more common transcription therapy targets include artificial zinc-finger constructs designed to compete or to regain control of specific target genes, peptides or small molecules that block protein interactions between the different levels, and small molecules that block the enzymatic activities of level-three proteins. The closer to the DNA-binding domain of the level-one protein, the greater the specificity and efficacy as per the prediction of our classification scheme, while the more distal targeting will encompass a greater spectrum of tumors. $ ¼ enzyme catalytic pockets. Targeting level-three proteins has therapeutic appeal since they represent common mechanisms involved in the transcriptional molecular pathogenesis of many tumors, and contain enzymatic activities considered to be amenable targets for small molecule drugs. Level-three proteins include (i) enzymes that covalently modify histones such as lysine deacetylases and acetylases (HDACs and HATs), lysine and arginine methyltransferases and demethylases, ubiquitin ligases, etc; (ii) enzymes that remodel nucleosomes in an ATP-dependent manner such as Brg1, Mi-2a and ISWI, and (iii) the DNA methyltransferases. The most extensive targeting experience to date involves two classes of drugs, the HDIs and DNA methyltransferase inhibitors (MTIs).
HDACs include 18 enzymes grouped into three families (class I, class II and sirtuins) that deacetylate lysine residues of histones and many other proteins. 14, 73 The term 'HDI' generally refers to drugs that inhibit the deacetylase activity of class I/II enzymes but not sirtuins, which have a different catalytic mechanism. 30 In accordance with our predictions, results to date suggest that HDIs profoundly affect the biology of tumor cells from a wide variety of histological backgrounds, although it is unclear whether transcriptional regulation is a key target in many of these instances. 43 In the phase I setting, with few exceptions, HDIs have modest antitumor activity as single agents, even at doses that induce potent histone hyperacetylation. [74] [75] [76] [77] [78] [79] If one considers this as the outcome of the transcriptional mechanism of action of these drugs, this is not entirely surprising, since transcription factors require a number of different activities to alter gene expression. A large number of phase II trials are underway, as are trials of HDIs in combination with other drugs, so it seems likely that HDIs will find several therapeutic applications. Interestingly, the disease in which HDIs seem most effective is cutaneous T-cell lymphomas. 80 The molecular and biological basis for the surprising efficacy of HDIs in this disease is unknown, and may or may not be related to direct effects of HDIs on transcription.
Regarding DNA methylation, oncogenic transcriptional repressors such as PML/RARa can recruit DNMTs to silence target genes. 81 However, in most cases, it is not known how DNMTs are recruited to establish oncogenic hypermethylation of tumor suppressor-associated CPG island promoters. 16 Exposure of many different cell types to the MTIs 5-azacytiine and 5-aza-2 0 deoxycytidine reverts CpG island hypermethylation and induces re-expression of silenced genes. 82 As CpG island hypermethylation is a frequent finding in tumor cells, many tumor cells respond to MTIs in vitro. However, like HDIs, MTIs also have additional effects in addition to DNMT blockade, which may explain in part their ability to suppress growth and induce apoptosis of tumor cells. 83, 84 In particular, DNA incorporation of these drugs triggers DNA damage response through p53, and possibly other damage response pathways. [85] [86] [87] In this way, these drugs behave like classical DNA-damaging agents, killing cells by triggering apoptosis through DNA damage checkpoints. Although clinical experience is limited, it appears that MTIs have activity in tumors such as myelodysplasias and leukemias. 88, 89 Therefore, MTIs also fulfill level-three predictions of broad, nontumor-specific activity, as well as the consequence of off-target gene effects. One such effect could be genomic instability, possibly due to loss of silencing of unstable intergenic DNA regions. 90 One way to partially circumvent the lack of efficacy or specificity of level-three drugs is to combine them. In this way, transcriptional events requiring both mechanisms are preferentially targeted, and transcription factors operating through both mechanisms are more effectively targeted. Accordingly, it has been demonstrated that histone deacetylation and DNA methylation cooperate to silence target genes, since methylCpG binding protein recruit HDACs, 91 oncogenic transcription factors such as PML/RARa recruit both HDACs and DNMTs, 81 and HDIs potentiate reactivation of genes by MTIs. 92 Thus, combining level-three agents might provide greater therapeutic efficacy, but on the other hand may also enhance undesired effects. For example, silencing of 'parasitic' DNA elements such as transposons and endogenous retrovirus depend on both mechanisms, and there is concern that these modalities could result in genomic instability due at least in part to reactivation of these elements. 90, 93, 94 Summary Transcription factors and cofactors are frequently altered in hematologic malignancies and play critical roles in molecular pathogenesis. Targeting these proteins and their mechanisms of action is a valid and potent form of specific molecular therapy for these diseases. The ability to identify the best targets and to forecast the activity of the agents that target them will be useful in considering how to best employ novel transcription therapy agents in both preclinical and clinical trials. We therefore suggest a framework for comparing and contrasting the mechanism of action of such drugs and predicting their biological and therapeutic effects. We hope this discussion is constructive towards generating new questions and stimulating deliberation and further research in transcription therapy.
